Breaking News Instant updates and real-time market news.

CAH

Cardinal Health

$69.44

-0.29 (-0.42%)

, AVXS

AveXis

$89.95

-3.21 (-3.45%)

04:55
09/13/17
09/13
04:55
09/13/17
04:55

Morgan Stanley to hold a conference

15th Annual Global Healthcare Conference is being held in New York on September 11-13.

CAH

Cardinal Health

$69.44

-0.29 (-0.42%)

AVXS

AveXis

$89.95

-3.21 (-3.45%)

IBM

IBM

$145.76

0.9 (0.62%)

QHC

Quorum Health

$4.51

0.31 (7.38%)

HOLX

Hologic

$38.19

-1.01 (-2.58%)

CTLT

Catalent

ALGN

Align Technology

$185.66

1.54 (0.84%)

VEEV

Veeva

$57.31

-0.47 (-0.81%)

ZBH

Zimmer Biomet

$116.43

0.63 (0.54%)

REGN

Regeneron

$444.48

-0.63 (-0.14%)

TMO

Thermo Fisher

$194.04

0.47 (0.24%)

SRPT

Sarepta

$44.10

-0.48 (-1.08%)

EPZM

Epizyme

$17.10

-1.15 (-6.30%)

PODD

Insulet

$58.65

0.33 (0.57%)

  • 13

    Sep

  • 13

    Sep

  • 21

    Sep

  • 22

    Sep

  • 25

    Sep

  • 25

    Sep

  • 27

    Sep

  • 15

    Nov

CAH Cardinal Health
$69.44

-0.29 (-0.42%)

07/03/17
BARD
07/03/17
NO CHANGE
Target $75
BARD
Neutral
Cardinal Health confirms deal to buy Liberty Medical, says Baird
Baird analyst Eric Coldwell said that Cardinal Health has confirmed a deal to buy Liberty Medical, a direct-to-patient provider of diabetes supplies and products that is well known for its commercials featuring actor Wilford Brimley. The small deal, which is immaterial to his model, enhances Cardinal's direct-to-patient platform primarily in diabetes and likely also adds volume in ostomy and urology, Coldwell tells investors. He keeps a Neutral rating and $75 price target on Cardinal Health shares.
07/13/17
FBCO
07/13/17
NO CHANGE
Target $87
FBCO
Outperform
Cardinal Health price target raised to $87 from $81 at Credit Suisse
Credit Suisse analyst Erin Wilson Wright raised her price target for Cardinal Health to $87 from $81 given the company's recent acquisition of Medtronic's patient recovery business. The analyst reiterates an Outperform rating on the shares.
08/03/17
FBCO
08/03/17
NO CHANGE
Target $81
FBCO
Outperform
Cardinal Health price target lowered to $81 from $87 at Credit Suisse
Credit Suisse analyst Erin Wilson Wright lowered her price target for Cardinal Health to $81 from $87, citing on a "surprising" cut to 2018 EPS guidance primarily on incremental investment initiatives across its businesses, further defining 2018 as a transition year. The analyst reiterates an Outperform rating on the shares.
08/09/17
BARD
08/09/17
NO CHANGE
BARD
Neutral
AmerisourceBergen settlement ups odds of PharMerica switch, says Baird
Baird analyst Eric Coldwell said AmerisourceBergen's (ABC) 10-Q last week showed that the company and PharMerica (PMC) have tentatively agreed to settle their long-running legal fight, which he reads as significantly increasing the odds of AmerisourceBergen displacing incumbent Cardinal Health (CAH) after KKR (KKR) and minority investor Walgreens (WBA) complete their deal to buy PharMerica. Coldwell has a Neutral rating and $89 price target on AmerisourceBergen shares.
AVXS AveXis
$89.95

-3.21 (-3.45%)

09/06/17
LEHM
09/06/17
INITIATION
LEHM
Overweight
AveXis initiated with an Overweight at Barclays
Barclays initiated AveXis with an Overweight rating and $124 price target, citing AVXS-101 showing "impressive" clinical benefit in Ph1/2 study, which could result in it becoming a strong competitor to Spinraza.
08/28/17
NOMU
08/28/17
INITIATION
Target $52
NOMU
Reduce
AveXis initiated with a Reduce at Nomura Instinet
Nomura Instinet started AveXis with a Reduce rating and $52 price target.
08/29/17
08/29/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Esperion (ESPR) initiated with an Outperform at Northland. 2. Carter's (CRI) initiated with an Outperform at Macquarie. 3. DarioHealth (DRIO) initiated with a Buy at Aegis. 4. Helen of Troy (HELE) initiated with an Underperform at BofA/Merrill. 5. AveXis (AVXS) initiated with a Reduce at Nomura Instinet. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/06/17
LEHM
09/06/17
INITIATION
Target $104
LEHM
Overweight
Spark named top pick in U.S. SMid-Cap Biotechnology at Barclays
Barclays analyst Gena Wang after the close initiated coverage of the U.S. Small & Mid Cap Biotechnology industry with a Positive view. Her top industry pick is Spark Therapeutics (ONCE). The analyst sees de-risking clinical data for several novel therapies in the biotech sector, namely from Spark, BioMarin (BMRN), AveXis (AVXS), Alnylam (ALNY) and Puma Biotechnology (PBYI). Wang believes Spark's Luxturna in RPE-65-mediated inherited retinal dystrophies could be disruptive to current treatment paradigms.
IBM IBM
$145.76

0.9 (0.62%)

09/12/17
MSCO
09/12/17
NO CHANGE
MSCO
Overweight
Morgan Stanley sees new evidence of scaling of IBM's Watson Health
After hosting a meeting with Deborah DiSanzo, General Manager of IBM Watson Health, Morgan Stanley analyst Katy Huberty noted that the unit grew patients that used cognitive technologies by ten times in one year to 40,000 from 4,000. Additionally, the number of hospitals using Watson for Oncology and Watson for Genomics more than doubled, to 89 from 27 last year, added Huberty. The analyst, who sees IBM as uniquely positioned to address the $2T of wasted spending on health care, keeps an Overweight rating on the stock.
09/05/17
UBSW
09/05/17
NO CHANGE
Target $152
UBSW
Neutral
Blockchain and cognitive computing IBM's best recovery chance, says UBS
UBS analyst Steven Milunovich noted IBM's (IBM) legacy business remains in decline but he thinks technologies such as blockchain and cognitive computing are its best hope for recovery. The analyst sees blockchain as a differentiated growth opportunity and he believes IBM is ahead of Microsoft (MSFT), which is also looking to monetize the technology. Milunovich said IBM's earnings momentum is mediocre and he remains concerned about the company's 2018 outlook. Milunovich maintained his Neutral rating and $152 price target on IBM shares.
08/07/17
BERN
08/07/17
NO CHANGE
BERN
IBM Infrastructure Services may not recover in 2H17, says Bernstein
After IBM predicted that the revenue growth of its Infrastructure Services, or IS, business would rebound in 2H17, Bernstein analyst A.M. (Toni) Sacconaghi, Jr says this target won't be "a slam dunk" for the company. He notes that the company's overall services backlog, which he says has historically been a good proxy for IS, is down 4% year-over-year. Additionally, he is worried " about potential financial incentives IBM may have provided to IS customers to extend/re-new existing contracts early." The analyst says the company remains "in a turnaround," and he keeps a Sector Perform rating.
08/04/17
08/04/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Square (SQ) initiated with a Neutral at Wedbush. 2. Avis Budget (CAR) was initiated with an Overweight at JPMorgan while Hertz (HTZ) was initiated with a Neutral at the firm. 3. IBM (IBM) initiated with a Neutral at Wedbush. 4. Amtech Systems (ASYS) initiated with a Buy at Roth Capital. 5. Franklin Financial Network (FSB) initiated with a Market Perform at Hovde Group. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
QHC Quorum Health
$4.51

0.31 (7.38%)

05/12/17
05/12/17
NO CHANGE

Quorum Health signs agreement to divest two hospitals in Tennessee
Quorum Health has signed a definitive agreement to sell 45-bed Henderson County Community Hospital in Lexington, Tennessee, and 45-bed McKenzie Regional Hospital in McKenzie, Tennessee, and their associated assets, to SSH Tennessee. The divestiture is expected to close by August 1, subject to customary regulatory approvals and closing conditions.
04/04/17
DBAB
04/04/17
INITIATION
DBAB
Hold
Quorum Health initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Chris Rigg initiated Quorom Health with a Hold rating and a $5 price target.
06/06/17
MSCO
06/06/17
INITIATION
Target $3
MSCO
Underweight
Quorum Health initiated with an Underweight at Morgan Stanley
Morgan Stanley analyst Zack Sopcak initiated Quorum Health with an Underweight and a $3 price target saying long-term growth remains a questions and unemployment is higher than average in the company's markets.
HOLX Hologic
$38.19

-1.01 (-2.58%)

09/12/17
COWN
09/12/17
NO CHANGE
COWN
Cowen says cervical cancer recommendations a risk for Hologic, Becton Dickinson
Cowen analyst Doug Schenkel noted that the US Preventive Services Task Force recently released a draft recommendation on cervical cancer screening, which no longer recommends cotesting with both an HPV assay and cytology, which would be a negative for Hologic (HOLX) and Becton Dickinson (BDX) if the draft is implemented. If the draft is implemented, it is likely a positive for Roche (RHHBY), the only vendor with a primary screening HPV assay that is FDA approved, added Schenkel. However, the final recommendation statement can be materially different from the draft, he said.
08/03/17
GSCO
08/03/17
DOWNGRADE
GSCO
Buy
Hologic downgraded to Buy from Conviction Buy at Goldman Sachs
Goldman analyst Isaac Ro removed Hologic from the Conviction Buy List saying Q3 results were disappointing and the product cycle/balance sheet flexibility thesis has played out. Ro said the Q3 report raised new questions about the strategic rationale of the Cynosure transaction, future M&A strategy, and the company's organic growth rate. The analyst maintains a Buy rating and $47 price target on shares but said it will need to deliver consecutive earnings beat and a clearer path to sustained MSD organic growth before the multiple improves.
06/08/17
ADAM
06/08/17
NO CHANGE
Target $53
ADAM
Buy
Hologic 3D label expansion an incremental positive, says Canaccord
Canaccord analyst Mark Massaro noted Hologix announced a label expansion approval for its 3D tomo mammography system to include breast cancer screening for women with dense breast tissue. Massaro views this as an incremental positive to the company's diversified business. Massaro reiterated his Buy rating and $53 price target on Hologix shares.
05/11/17
STFL
05/11/17
NO CHANGE
STFL
Hologic should be bought on weakness, says Stifel
After Cynosure which was acquired by Hologic reported weaker than expected Q2 results, Stifel analyst Jonathan Block thinks that Cynosure's issues are "transient," as he believes that it will be improved soon. He raised his price target on Hologic to $48 from $45 and recommends buying the stock on weakness. He keeps a Buy rating on the shares.
CTLT Catalent

09/07/17
KEYB
09/07/17
DOWNGRADE
KEYB
Sector Weight
Catalent downgraded to Sector Weight from Overweight at KeyBanc
09/12/17
NEED
09/12/17
INITIATION
NEED
Hold
Catalent initiated with a Hold at Needham
08/29/17
JPMS
08/29/17
NO CHANGE
Target $40
JPMS
Overweight
Catalent price target raised to $40 from $34 at JPMorgan
JPMorgan analyst Tycho Peterson raised his price target for Catalent shares to $40 saying the company reported strong Q4 results. As the global leader in the drug delivery outsourcing market, the company "sits at the nexus of several favorable secular trends," Peterson tells investors in a post-earnings research note. He keeps an Overweight rating on the shares.
09/08/17
KEYB
09/08/17
DOWNGRADE
KEYB
Sector Weight
Catalent downgraded to Sector Weight on valuation at KeyBanc
KeyBanc analyst Matthew Mishan last night downgraded Catalent to Sector Weight from Overweight citing valuation. Investor sentiment has improved significantly year-over-year, Mishan tells investors in a research note. He notes the shares have exceeded his previous price target.
ALGN Align Technology
$185.66

1.54 (0.84%)

09/11/17
PIPR
09/11/17
NO CHANGE
Target $200
PIPR
Overweight
Align Technology price target raised to $200 from $188 at Piper Jaffray
Piper Jaffray analyst Matt O'Brien raised his price target for Align Technology to $200 after attending the Invisalign GP Summit this past weekend. The analyst left the meeting feeling the company's iTero is much more vital to the general practitioner workflow than previously thought and that moving teeth is growing into an increasingly important piece of the GP practice. He calls Align a "one of a kind" name and tells investors to build positions at current levels. O'Brien keeps an Overweight rating on the shares.
08/18/17
WBLR
08/18/17
NO CHANGE
WBLR
Outperform
Align selloff on ClearCorrect takeover overdone, says William Blair
William Blair analyst John Kreger believes the selloff yesterday in shares of Align Technology after Straumann announced that it was acquiring ClearCorrect is overdone. The analyst does not think Straumann buying ClearCorrect affects Align's growth outlook He continues to expect Align's success at migrating traditional orthodontics to clear aligners will attract new competitors. Kreger keeps an Outperform rating on Align shares.
08/18/17
JEFF
08/18/17
NO CHANGE
JEFF
Buy
Jefferies doesn't see ClearCorrect buyout changing market dynamics
Jefferies analyst Brandon Couillard believes Straumann's acquisition of ClearCorrect will not materially change the landscape or market dynamics for Align Technology (ALGN). The deal, however, has "rekindled competitive concerns," the analyst tells investors in a research note. Straumann's move validates Align's view that orthodontia is undergoing a secular shift from analog to digital modalities, Couillard argues. He believes the acquisition does not represent a threat for Align's core ortho practitioner market.
09/06/17
PIPR
09/06/17
NO CHANGE
PIPR
Overweight
Align patent expirations to have minimal impact, says Piper Jaffray
About 40 of Align Technology's patents are about to expire, which will allow competitors for the first time to plan cases using computer assistance, Piper Jaffray analyst Matt O'Brien tells investors in a research note. The analyst, however, believes only a "modest part" of Align's revenue, maybe $20M-$30M, could be at risk. He still sees the company growing in its traditional range of 15%-25% on the top-line and encourages investors to build positions in the name. Olson raised his price target for Align Technology shares to $188 from $176 and keeps an Overweight rating on the name.
VEEV Veeva
$57.31

-0.47 (-0.81%)

06/05/17
06/05/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Apple (AAPL) downgraded to Sector Weight from Overweight at Pacific Crest with analyst Andy Hargreaves saying upside from the launch of iPhone 8 is already reflected in the shares. An "extremely strong iPhone 8 cycle" is being priced into the stock while little weight is being given to gross margins, supply issues, or the likelihood for declines beyond the iPhone 8, Hargreaves tells investors in a research note. 2. Perrigo (PRGO) downgraded to Underperform from Sector Perform at RBC Capital with analyst Randall Stanicky saying the growth rate of the company's U.S. consumer business "has structurally re-rated lower" amid pricing headwinds and share losses. 3. Endocyte (ECYT) downgraded to Neutral from Outperform at Wedbush and to Market Perform from Outperform at Cowen. 4. Affiliated Managers (AMG) was downgraded to Neutral from Buy at Citi while Federated Investors (FII) was downgraded to Sell from Neutral. 5. Veeva (VEEV) downgraded to Equal Weight from Overweight at Morgan Stanley with the firm's analyst saying the 60%+ move in shares year-to-date captures much of the near-term upside in the stock. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/25/17
JMPS
08/25/17
NO CHANGE
JMPS
Veeva weakness creates buying opportunity, says JMP Securities
JMP Securities analyst Rishi Jaluria says that Veeva reported "strong" Q2 results. The analyst says that the stock may have declined because the company's results, although above the consensus outlook, could have come in below investors' expectations. The analyst adds that although the company did not sign any new customers outside of the life sciences vertical for its Vault system, its momentum in this area "remains strong," as its top five consumer packaged goods customers are expanding their deals with the company. The analyst is more upbeat on the company's outlook following the results and recommends buying the shares on weakness.
06/05/17
MSCO
06/05/17
DOWNGRADE
Target $68
MSCO
Equal Weight
Veeva downgraded to Equal Weight due to valuation at Morgan Stanley
As previously reported, Morgan Stanley downgraded Veeva to Equal Weight from Overweight and raised its price target to $68 from $53. The analyst said the 60%+ move in shares year-to-date captures much of the near-term upside in the stock. .
06/05/17
MSCO
06/05/17
DOWNGRADE
MSCO
Equal Weight
Veeva downgraded to Equal Weight from Overweight at Morgan Stanley
ZBH Zimmer Biomet
$116.43

0.63 (0.54%)

08/24/17
08/24/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Zimmer Biomet (ZBH) initiated with a Buy at Gabelli. 2. Foamix (FOMX) initiated with a Buy at H.C. Wainwright. 3. Netlist (NLST) initiated with a Buy at Roth Capital. 4. Flexion (FLXN) initiated with an Outperform at Northland. 5. USA Technologies (USAT) initiated with an Outperform at William Blair. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/04/17
RHCO
08/04/17
NO CHANGE
RHCO
Zimmer Biomet shares undervalued, says SunTrust
SunTrust analyst Bruce Nudell says that Zimmer could accelerate its revenue growth to 4%+ from 3% by selling its dental unit and making acquisitions. The analyst adds that the company's "knee product gap/inventory headwinds" should end over the next 6-18 months. He thinks that the shares are undervalued despite the company's recent "underwhelming" results and his belief that it will have difficulty defending its market share in the hip/knee market. The analyst trimmed his price target on the shares to $136 from $145 and keeps a Buy rating on the stock.
08/14/17
OPCO
08/14/17
NO CHANGE
Target $137
OPCO
Outperform
Zimmer Biomet stock reaction greater than any likely impact, says Oppenheimer
Oppenheimer analyst Steven Lichtman notes that Zimmer Biomet's disclosure in its Q2 Form 10-Q that it has received an OIG subpoena has caused further weakness in the shares. The analyst thinks the stock reaction is greater than any likely impact near or long-term. He reiterates an Outperform rating and $137 price target on the shares.
08/24/17
GABE
08/24/17
INITIATION
GABE
Buy
Zimmer Biomet initiated with a Buy at Gabelli
Gabelli analyst Jennie Tsai initiated Zimmer Biomet with a Buy and a $142 PMV per share saying the CEO change is a major catalysts and shares remain one of the most undervalued companies in the orthopedic market. The analyst expects the new CEO will drive sustainable sales and earnings growth over time.
REGN Regeneron
$444.48

-0.63 (-0.14%)

09/07/17
PIPR
09/07/17
NO CHANGE
Target $557
PIPR
Overweight
Regeneron selloff today a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff notes shares of Regeneron Pharmaceuticals (REGN) are trading lower after Phase IIb readouts from competitors Amgen (AMGN) and AstraZeneca (AZN) in asthma and AbbVie (ABBV) in atopic dermatitis met their primary endpoints. The analyst does not see an "immediate competitive threat" to Regeneron's Dupixent, which he says has successfully launched in atopic dermatitis following FDA approval in March. He recommends buying the shares on today's selloff ahead of expected "positive" Phase III Dupixent asthma data. Dupixent maintains at least a two-year lead ahead of these competitive agents, Tenthoff tells investors in an intraday research note. The analyst reiterates an Overweight rating on Regeneron with a $557 price target.
09/11/17
FBCO
09/11/17
NO CHANGE
Target $485
FBCO
Outperform
Regeneron, Sanofi asthma trial 'statistically significant,' says Credit Suisse
Credit Suisse analyst Alethia Young notes that Regeneron (REGN)/Sanofi (SNY) released top-line asthma results, and the overall trial was "statistically significant." Specifically, the trial hit in the overall population, but it is unclear if the trial was statistically significant in the low eosinophil level patients alone, she notes. The analyst reiterates an Outperform rating and $485 price target on Regeneron's shares.
09/11/17
PIPR
09/11/17
NO CHANGE
Target $557
PIPR
Overweight
Regeneron pullback today a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff recommends using today's weakness in shares of Regeneron Pharmaceuticals as a buying opportunity. The analyst calls the Phase III Quest data in severe asthma patients positive and projects peak U.S. asthma sales of $2.2B by 2025. He reiterates an Overweight rating on Regeneron with a $557 price target. The stock in early trading is down 6% to $443.39.
09/07/17
PIPR
09/07/17
NO CHANGE
Target $193
PIPR
Overweight
Amgen still has long way to go in asthma, says Piper Jaffray
After last night's Phase 2 trial data of Amgen's (AMGN) tezepelumab in severe asthma, Piper Jaffray analyst Christopher Raymond says the drug "looks to be in the ballpark but still numerically short of the mark" when compared with Regeneron's (REGN) Dupixent's Phase 2 profile. He thinks full Phase 3 data will be the ultimate determinant of the relative merits of each mechanism and reminds investors that such data have not been seen for either drug. In a research note titled, "Tezepelumab Phase 2 Asthma Data Gets Amgen in the Game, But Still a Long Way to Go," James keeps an Overweight rating on Amgen, while noting tezepelumab, with Phase 3 data likely a few years out, is not in his valuation model.
TMO Thermo Fisher
$194.04

0.47 (0.24%)

07/20/17
CLVD
07/20/17
UPGRADE
CLVD
Buy
Thermo Fisher upgraded to Buy on strong trends at Cleveland Research
As previously reported, Cleveland Research upgraded Thermo Fisher to Buy from Neutral with a $206 price target. Analyst Steve Willoughby said checks indicate Pharma customer demand remains strong while Industrial and Academic demand appears to be improving. As a result, the analyst now sees upside to management's guidance of 4% organic growth guidance in 2017 and sees further upside in shares from improving fundamentals.
09/06/17
MSCO
09/06/17
INITIATION
Target $220
MSCO
Overweight
Thermo Fisher resumed with an Overweight at Morgan Stanley
Morgan Stanley analyst Steve Beuchaw resumed coverage of Thermo Fisher with an Overweight rating and $220 price target, contending that consensus EPS estimates for 2018 and 2019 are too low and that the company's longer-term opportunity in the highly fragmented CDMO market is underappreciated.
08/22/17
ARGS
08/22/17
NO CHANGE
ARGS
Thermo Fisher price target raised to $200 from $180 at Argus
Argus analyst David Toung raised his price target on Thermo Fisher after the company agreed to buy Patheon, a contract development and manufacturing organization. The analyst calls Patheon "a growth driver" and says that it will help Thermo Fisher integrate other, future acquisitions. Calling Thermo Fisher's valuation "attractive," the analyst keeps a Buy rating on the stock.
07/26/17
WELS
07/26/17
NO CHANGE
Target $200
WELS
Outperform
Thermo Fisher weakness a buying opportunity, says Wells Fargo
Wells Fargo analyst Tim Evans would use weakness in Thermo Fisher shares as a buying opportunity saying his long-term positive view of the pharma market is unchanged, but investor expectations may be a bit too high. Evans said Thermo has more flexibility on capital deployment than peers, giving it advantages when it comes to acquisitions or share repurchases. Shares are Outperform rated with a $200 price target.
SRPT Sarepta
$44.10

-0.48 (-1.08%)

09/07/17
FBCO
09/07/17
NO CHANGE
Target $81
FBCO
Outperform
Sarepta price target raised to $81 from $64 at Credit Suisse
Credit Suisse analyst Alethia Young raised her price target last night for shares of Sarepta Therapeutics to $81 following yesterday's top line results from the company's Exon 53 study dosed in 25 patients. The analyst now assumes a slightly higher probability of success for ongoing pivotal Essence study. She increased her probability of success to 40% in both exons and keeps an Outperform rating on Sarepta. The shares closed yesterday up $5.65, or 14%, to $46.73.
09/06/17
LEHM
09/06/17
INITIATION
Target $46
LEHM
Equal Weight
Sarepta initiated with an Equal Weight at Barclays
Barclays analyst Gena Wang started Sarepta Therapeutics with an Equal Weight rating and $46 price target. The analyst believes expectations for a strong Exondys 51 launch are largely priced into the shares.
09/06/17
PIPR
09/06/17
NO CHANGE
Target $55
PIPR
Overweight
Piper ups Sarepta target to $55 on positive golodirsen data
Piper Jaffray analyst Edward Tenthoff raised his price target for Sarepta Therapeutics to $55 citing the "positive" muscle biopsy data from the Phase I/II 4053-101 study of exon 53 skipping drug golodirsen in 25 Duchenne muscular dystrophy boys. The shares in morning trading are up 11%, or $4.56, to $45.67. The analyst views the data as encouraging and keeps an Overweight rating on Sarepta shares.
09/07/17
OPCO
09/07/17
NO CHANGE
Target $76
OPCO
Outperform
Data removes another overhang on Sarepta, says Oppenheimer
Oppenheimer analyst Hartaj Singh notes that Sarepta provided an update on its 4053-101 study, a two-part study designed to assess the safety, tolerability and pharmacokinetics of four dose levels of SRP-4053 and an open-label evaluation of SRP-4053 in patients with deletions amenable to exon 53 skipping. The positive result removes an overhang on Sarepta, he contends, as some investors had posited that weak biopsy results from 4053-101 could reignite the Exondys 51 approval controversy from 2H16. The analyst reiterates an Outperform rating and $76 price target on the shares.
EPZM Epizyme
$17.10

-1.15 (-6.30%)

06/14/17
LEER
06/14/17
NO CHANGE
Target $31
LEER
Outperform
Epizyme data suggests accelerated filing possible for tazemetostat, says Leerink
Leerink analyst Geoffrey Porges said the updated tazemetostat data in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma grouped by EZH2 mutation was positive, as the response rate and long durations in EZH2 FL are "compelling" and the updated safety data reinforce the possibility for future combination trials. Given the data, Porges believes an accelerated filing and approval is possible for EZH2 FL. He keeps an Outperform rating and $31 price target on Epizyme shares.
06/15/17
SBSH
06/15/17
NO CHANGE
Target $22
SBSH
Buy
Citi sees accelerated approval for Epizyme, ups price target
Epizyme's data yesterday for tazemetostat showed a "strong response" in follicular lymphoma patients with the EZH2 mutation and activity in other indications, Citi analyst Robyn Karnauskas tells investors in a research note. She believes the data support accelerated approval and raised her price target for the shares to $22 from $20. The analyst keeps a Buy rating on Epizyme.
06/05/17
JMPS
06/05/17
NO CHANGE
JMPS
Epizyme data positive, says JMP Securities
After Epizyme presented interim data from the epithelioid sarcoma and synovial sarcoma cohorts of its ongoing Phase II trial of tazemetostat, JMP Securities analyst Michael King says that the overall survival rate of those patients who have responded to treatments "provides an early but robust indication of tazemetostat's potential for providing clinical benefit in this patient population." He keeps a $28 price target and Outperform rating on the stock.
06/15/17
RHCO
06/15/17
NO CHANGE
Target $21
RHCO
Buy
SunTrust ups odds of success for Epizyme's tazemetostat in follicular lymphoma
Following data presented at a lymphoma conference and the associated call held by Epizyme management, SunTrust analyst Peter Lawson increased his view of the probability of success and penetration for tazemetostat in follicular lymphoma patients with EZH2 mutations. The analyst, who adds that tazemetostat's favorable side effect profile bodes well for its potential use in a maintenance setting, keeps a Buy rating and $21 price target on Epizyme shares.
PODD Insulet
$58.65

0.33 (0.57%)

07/13/17
BTIG
07/13/17
NO CHANGE
BTIG
Buy
Abbott, Bigfoot deal a 'major validation' for both, says BTIG
BTIG analyst Sean Lavin sees Abbott's (ABT) deal to collaborate with Bigfoot Biomedical as a major validation of both Abbott's Libre technology and the platform of Bigfoot, which he views as a leader in the development of automated pancreases. For Dexcom (DXCM), this is a missed opportunity that could also be a sign that its grip on the CGM market may fade over time, but the company still has multiple shots with other pump systems and remains the market leader of standalone CGM, said Lavin. Insulet (PODD) is well underway in developing its Horizon AP platform and is unlikely to switch from Dexcom for its CGM, added Lavin, who keeps a Buy rating on Abbott and a Neutral rating on Dexcom.
07/17/17
BTIG
07/17/17
DOWNGRADE
BTIG
Neutral
Insulet downgraded to Neutral from Buy at BTIG
BTIG analyst Sean Lavin downgraded Insulet to Neutral saying shares are fairly valued following recent share strength.
08/04/17
COWN
08/04/17
NO CHANGE
Target $63
COWN
Outperform
Insulet price target raised to $63 from $52 at Cowen
Cowen analyst Doug Schenkel raised his price target on Insulet to $63 from $52 following solid Q2 results. The analyst raised his estimates to account for the company going direct in Europe while also raising his long-term gross margin target. Schenkel, who also continues to see upside to 2019 estimates, reiterated his Outperform rating on Insulet shares.
07/11/17
ADAM
07/11/17
NO CHANGE
Target $50
ADAM
Hold
Insulet fundamental set-up best in years, says Canaccord
Canaccord analyst Kyle Rose said his survey following last month's ADA conference showed an increasing demand for insulin pumps as well as expectations that Insulet's Dash product will gain market share over the next 18 months. He believes the company is entering a period of product cycle growth, leaving him increasingly bullish. Rose maintained his Hold rating but raised his price target to $50 from $42 on Insulet shares.

TODAY'S FREE FLY STORIES

KMX

CarMax

$68.84

0.17 (0.25%)

, FINL

Finish Line

$9.22

-0.21 (-2.23%)

20:25
09/21/17
09/21
20:25
09/21/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

KMX

CarMax

$68.84

0.17 (0.25%)

FINL

Finish Line

$9.22

-0.21 (-2.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 22

    Sep

HPE

HP Enterprise

$13.79

0.16 (1.17%)

18:47
09/21/17
09/21
18:47
09/21/17
18:47
Periodicals
HP Enterprise planning approximately 5,000 job cuts, Bloomberg reports »

In part of a broader…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 11

    Dec

RP

RealPage

$39.35

-0.1 (-0.25%)

18:41
09/21/17
09/21
18:41
09/21/17
18:41
Hot Stocks
RealPage expects $3M-$4M of renter's insurance claims from hurricanes »

RealPage announced that a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPE

HP Enterprise

$13.79

0.16 (1.17%)

18:39
09/21/17
09/21
18:39
09/21/17
18:39
Periodicals
Breaking Periodicals news story on HP Enterprise »

HP Enterprise planning…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 11

    Dec

YUM

Yum! Brands

$76.48

0.11 (0.14%)

18:37
09/21/17
09/21
18:37
09/21/17
18:37
Conference/Events
Yum! Brands management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

MAR

Marriott

$107.57

-0.12 (-0.11%)

18:32
09/21/17
09/21
18:32
09/21/17
18:32
Conference/Events
Marriott management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

ESPGY

Esprit Holdings

$1.21

0.018 (1.51%)

18:29
09/21/17
09/21
18:29
09/21/17
18:29
Conference/Events
Esprit Holdings management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

BA

Boeing

$256.04

0.58 (0.23%)

18:18
09/21/17
09/21
18:18
09/21/17
18:18
Hot Stocks
Boeing: Turkish Airlines announces intent to order 40 787-9 Dreamliners »

Boeing and Turkish…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

M

Macy's

$21.16

-0.32 (-1.49%)

18:18
09/21/17
09/21
18:18
09/21/17
18:18
Conference/Events
Macy's management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

TAHO

Tahoe Resources

$5.60

0.02 (0.36%)

18:12
09/21/17
09/21
18:12
09/21/17
18:12
Hot Stocks
Tahoe Resources raises 2017 gold operations view to 400K-500K »

Tahoe Resources updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATKR

Atkore

$18.42

0.02 (0.11%)

18:11
09/21/17
09/21
18:11
09/21/17
18:11
Conference/Events
Atkore management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

YOGA

YogaWorks

$4.00

-0.04 (-0.99%)

, TXN

Texas Instruments

$86.05

0.22 (0.26%)

18:11
09/21/17
09/21
18:11
09/21/17
18:11
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

YOGA

YogaWorks

$4.00

-0.04 (-0.99%)

TXN

Texas Instruments

$86.05

0.22 (0.26%)

PSDO

Presidio

$13.95

-0.06 (-0.43%)

VSAR

Versartis

$21.60

-0.25 (-1.14%)

ASND

Ascendis Pharma

$27.74

-1.55 (-5.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 21

    Sep

FTR

Frontier Communications

$11.69

-0.31 (-2.58%)

18:10
09/21/17
09/21
18:10
09/21/17
18:10
Hot Stocks
Frontier Communications operations in Florida return to near-normal levels »

Daily operations for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLYA

Playa Hotels & Resorts

$10.66

-0.06 (-0.56%)

18:07
09/21/17
09/21
18:07
09/21/17
18:07
Hot Stocks
Playa Hotels & Resorts reports no significant damage from Maria »

Playa Hotels &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

ASND

Ascendis Pharma

$27.74

-1.55 (-5.29%)

, VSAR

Versartis

$21.60

-0.25 (-1.14%)

18:07
09/21/17
09/21
18:07
09/21/17
18:07
Hot Stocks
Ascendis spikes higher after Versartis Velocity trial fails to meet endpoint »

Shares of Ascendis Pharma…

ASND

Ascendis Pharma

$27.74

-1.55 (-5.29%)

VSAR

Versartis

$21.60

-0.25 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$103.90

-0.04 (-0.04%)

18:04
09/21/17
09/21
18:04
09/21/17
18:04
Hot Stocks
Celanese increases price of acetyl intermediates »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DNOW

NOW Inc.

$12.98

0.1 (0.78%)

18:03
09/21/17
09/21
18:03
09/21/17
18:03
Conference/Events
NOW Inc. management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 01

    Nov

JOBS

51job

$58.50

0.01 (0.02%)

18:02
09/21/17
09/21
18:02
09/21/17
18:02
Hot Stocks
51job announces strategic investment in Lagou »

51job announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HES

Hess Corp.

$43.63

0.17 (0.39%)

17:53
09/21/17
09/21
17:53
09/21/17
17:53
Conference/Events
Hess Corp. management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

APC

Anadarko

$48.49

3.68 (8.21%)

17:43
09/21/17
09/21
17:43
09/21/17
17:43
Recommendations
Anadarko analyst commentary at MUFG »

Anadarko buyback a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

HCC

Warrior Met Coal

$23.28

-1.05 (-4.32%)

17:42
09/21/17
09/21
17:42
09/21/17
17:42
Hot Stocks
Warrior Met Coal receives favorable IRS private letter ruling »

Warrior Met Coal reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAA

MAA

$107.27

-0.03 (-0.03%)

17:35
09/21/17
09/21
17:35
09/21/17
17:35
Hot Stocks
MAA announces estimated impact of Hurricanes Irma and Harvey »

MAA announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOC

Northrop Grumman

$280.42

0.38 (0.14%)

17:31
09/21/17
09/21
17:31
09/21/17
17:31
Hot Stocks
Northrop Grumman awarded $124.7M government contract »

Northrop Grumman Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GD

General Dynamics

$205.72

1.45 (0.71%)

17:29
09/21/17
09/21
17:29
09/21/17
17:29
Hot Stocks
General Dynamics Electric Boat awarded $5B government contract »

General Dynamics Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAN

Aaron's

$38.83

-0.39 (-0.99%)

17:19
09/21/17
09/21
17:19
09/21/17
17:19
Hot Stocks
Aaron's provides update on impact of Hurricane Irma »

Aaron's plans to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.